Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.

ABSTRACT:

Background

Real-world evidence (RWE) can provide postmarket data to inform whether funded cancer drugs yield expected outcomes and value for money, but it is unclear how to incorporate RWE into Canadian cancer drug funding decisions. As part of the Canadian Real-World Evidence Value for Cancer Drugs (CanREValue) Collaboration, this study aimed to explore stakeholder perspectives on the current state of RWE in Canada to inform a Canadian framework for use of RWE in cancer drug funding decisions.

Methods

This was a qualitative descriptive study. Qualitative semistructured interviews were conducted from April to July 2018. Participants were Canadian and international stakeholders who had experience with RWE and drug funding decision-making. Thematic analysis was used to analyze

SUBMITTER: Clausen M 

PROVIDER: S-EPMC7721249 | biostudies-literature | 2020 Oct-Dec

REPOSITORIES: biostudies-literature